Neurocrine Biosciences has been granted a patent for a method of treating classical Congenital Adrenal Hyperplasia (CAH) using a CRF1 receptor antagonist. The antagonist has the potential to inhibit ACTH release, allowing for lower doses of hydrocortisone and reducing treatment side effects. The specific antagonist mentioned in the claim is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyn-1-yl)-2-thiazolamine (SSR-125543). GlobalData’s report on Neurocrine Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Neurocrine Biosciences, Cancer treatment biomarkers was a key innovation area identified from patents. Neurocrine Biosciences's grant share as of September 2023 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Treating classical congenital adrenal hyperplasia with crf1 receptor antagonist
A recently granted patent (Publication Number: US11730739B2) discloses a method for treating classical Congenital Adrenal Hyperplasia (CAH) using a specific CRF1 receptor antagonist called SSR-125543. The method involves administering an effective amount of the antagonist to a subject in need of treatment. The patent claims specify various aspects of the method, including the timing of administration, the specific form of the antagonist, and the inclusion of additional treatments.
According to the patent claims, the CRF1 receptor antagonist can be administered at bedtime or at or before the expected circadian release of ACTH, which is a hormone involved in CAH. The antagonist can be administered 3-4 hours before the expected release of ACTH. The specific antagonist mentioned in the claims is SSR-125543.
The method is specifically intended for treating classical CAH caused by 21-hydroxylase deficiency and excludes subjects with a mutation of the 11ß-hydroxylase gene CYP11B1. Prior to administration, the subject should exhibit elevated levels of 17-hydroxyprogesterone (17-OHP), adrenocorticotropic hormone (ACTH), and androstenedione. Subsequent to administration, the subject should exhibit reduced levels of these hormones compared to their levels prior to treatment.
The patent claims also mention the administration of glucocorticoid treatment, such as hydrocortisone, dexamethasone, prednisone, or prednisolone, to the subject. Additionally, a salt-wasting mineralocorticoid, specifically fludrocortisone, can be administered. The claims further specify the various forms in which the antagonist can be administered, including liquid, solid, semi-solid formulations, tablets, powders, granules, or capsules.
The method can be applied to both adult and child subjects, as well as female subjects. Monitoring for potential side effects and complications is also mentioned in the claims, including the development of iatrogenic Cushing's syndrome, Addisonian syndrome, hypertension, low blood pressure, salt loss, fatigue, and increased requirements for glucocorticoids.
In summary, the granted patent describes a method for treating classical CAH using a specific CRF1 receptor antagonist called SSR-125543. The method involves administering the antagonist at specific timings and in specific forms, along with additional glucocorticoid and mineralocorticoid treatments. The claims also mention the importance of monitoring for potential side effects and complications.
To know more about GlobalData’s detailed insights on Neurocrine Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
